Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Neoplasms 4Neoplasm Metastasis 3Melanoma 3Head and Neck Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Esophageal Neoplasms 2Colorectal Neoplasms 2Triple Negative Breast Neoplasms 1Solid Tumor, Adult 1Solid Tumor 1Skin Neoplasms 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1NSCLC 1Meningeal Carcinomatosis 1Lymphoma 1Lung Neoplasms 1Kidney Neoplasms 1Hematologic Neoplasms 1Glioma 1Esophageal Squamous Cell Carcinoma 1Diffuse Intrinsic Pontine Glioma 1

Interventions

aflutinib 3osimertinib 2Radiotherapy 2tipifarnib 1apatinib 1Radiosurgery 1Immune Checkpoint Inhibitors 1Gefitinib 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × NSCLC × Immune Checkpoint Inhibitors × Clear all
NCT05615142 2026-05-11

Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.

Sichuan University

Phase 1 Active not recruiting
9 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡